Profile photo

GU Oncology Now

Genitourinary Oncology

GU Oncology Now delivers the latest news in therapeutics, clinical trials, conference coverage, and more, highlighting important advancements in genitourinary oncology treatments and technologies with the goal of better informing oncology decisions and improving patient outcomes.

The Latest in Advanced Bladder Cancer Research: Benefit of EV/Pembrolizumab

Preheader: Plus: Olaparib for DDR Alterations, New Drug Application for Erdafitinib, and More |

Dear readers,

New developments in metastatic and advanced bladder cancer research are taking the spotlight this month, particularly enfortumab vedotin plus pembrolizumab. Not only have the 2 drugs shown a survival benefit as individual treatments, but the combination has demonstrated benefit as a first-line treatment for cisplatin-ineligible patients. Dr. Shilpa Gupta and Senior Clinical Research Coordinator Tanya Jindal share insight on the EV-103 and UNITE studies focusing on the drugs. We also included new data on olaparib and erdafitinib.

We hope you enjoy!

Want to view more? Visit our website.

 

GU Oncology Now

Articles
  • Mashup Score: 0
    FDA Round-Up: Erdafitinib for mUC, Enzalutamide for nmCSPC - 2 year(s) ago

    Multiple genitourinary oncology therapies are in the spotlight this week, with new US Food and Drug Administration (FDA) indications potentially on the horizon. The Janssen Pharmaceutical Companies of Johnson & Johnson announced their submission of a supplemental New Drug Application (sNDA) seeking full approval of BALVERSA (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) who have a susceptible fibroblast growth factor receptor (FGFR)3

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      Multiple genitourinary oncology therapies have recently been in the spotlight, including #erdafitinib for urothelial carcinoma and #enzalutamide for nonmetastatic castration-sensitive #prostatecancer. See the new developments for these treatments: https://t.co/15nQZwtfUD https://t.co/BpSg68zayE

  • Mashup Score: 0
    EV Plus Pembrolizumab Demonstrates High cORR, Durable Responses in Cisplatin-Ineligible Patients With mUC - 2 year(s) ago

    There are limited first-line (1L) treatment options for patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy, and improved therapies are needed. Enfortumab vedotin (EV) and pembrolizumab have shown a survival benefit as individual treatments in the second-line and la/mUC settings. Researchers recently published new data on cohort K of the EV-103 phase 1b/2 study that investigated EV alone or combined with pembrolizumab in cisplatin-ineligibl

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      Enfortumab vedotin and #pembrolizumab have shown a survival benefit as individual treatments in locally advanced and metastatic urothelial cancer, but are they just as effective as a combination treatment? Read what new research has uncovered: https://t.co/4iaTYdEhNu https://t.co/NkQR45aTuD

  • Mashup Score: 0
    DDR Mutations Not Linked to Clinical Benefit of Olaparib in mUC - 2 year(s) ago

    Poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors may offer a therapeutic benefit in patients with metastatic urothelial cancer (mUC). PARP inhibitors are the first approved targeted agent to manage DNA damage response (DDR) genes and have demonstrated a clinical benefit in patients with solid tumors who carry germline or somatic alterations in those genes. As somatic alterations in DDR genes are common in patients with advanced urothelial cancer, researchers examined the use of the PARP

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      Researchers examined the use of the PARP inhibitor #olaparib to determine the drug’s potential therapeutic benefit in patients with metastatic #urothelialcarcinoma with somatic DDR alterations: https://t.co/AERD3wrF5t https://t.co/BfHvgt1iNm

  • Mashup Score: 5
    Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE Study - 2 year(s) ago

    Home > ASCO 2023 > Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE Study Tanya Jindal, Senior, Clinical Research Coordinator, University of California, San Francisco, highlights and expands upon the findings of the UNITE study relative to biomarkers of response to sacituzumab govitecan and enfortumab vedotin for patients with advanced urothelial carcinoma. Can you describe the UNITE study? What was the design, what types of patients were included, and how did

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      .@Tanjin097 of @UCSFCancer shares her analysis of the UNITE study on the molecular biomarkers associated with outcomes after treatment with enfortumab vedotin for advanced #bladdercancer. https://t.co/8dZoB9Tdg3 @koshkin85 https://t.co/qlhXdCZFSj

  • Mashup Score: 15
    Drs. Gupta, Koshkin on EV-103 Design and Long-Term Cohort A Results for Patients With aUC - 2 year(s) ago

    Home > ASCO 2023 > Drs. Gupta, Koshkin on EV-103 Design and Long-Term Cohort A Results for Patients With aUC Dr. Gupta: Sure, EV-103 is an open-label multiple cohort Phase Ib2 study with various cohorts. Cohort A comprised patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin. The cohort had a dose escalation portion with 5 patients, followed by a dose expansion with 40 patients. Additionally, there was cohort K, a randomized study comparing EV with pembro versus

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      What does 4-year duration of response and objective response rate signal for EV/pembro in cisplatin-ineligible locally advanced or metastatic #bladdercancer? @shilpaonc and @koshkin85 weigh the encouraging data...https://t.co/tMwS686lZo https://t.co/ddvoYDXcqb